SEC Tracker
Get the app

Olema Pharmaceuticals OLMA

Olema Pharmaceuticals reports director changes

Reports an executive or board change

Form
8-K
Filed
Importance
Major
  1. Dr. Gorjan Hrustanovic resigned from Olema's Board on Oct 14, 2026
  2. Dr. Hrustanovic left Compensation and Science committees
  3. Dr. Prakash Raman joined Compensation and Science committees on Oct 15, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Olema Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The report is made under Item 5.02, which covers the departure of directors or certain officers and the appointment of certain officers.
  2. Under Item 5.02, Dr. Gorjan Hrustanovic notified the company on October 12, 2026 that he decided to resign from the Board of Directors, effective October 14, 2026.
  3. He also resigned from the Compensation Committee and the Science and Technology Committee.
  4. The filing states that Dr. Hrustanovic's resignation was not the result of any disagreement with the company on any matter relating to its operations, policies or practices.
  5. The company thanks him for his service and contributions to the company and the Board.
  6. The report is signed by Sean Bohen, M.D., Ph.D., President and Chief Executive Officer.

6 of 6 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • For context, in its 10-Q for the quarter ended June 30, 2026, Olema reported net income of -$63.2 million.

From the filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.1

On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the "Company") of his decision to resign from the Company's Board of Directors (the "Board"), effective October 14, 2026.2 Dr. Hrustanovic also resigned from the Compensation Committee of the Board (the "Compensation Committee") and the Science and Technology Committee of the Board (the "Science and Technology Committee").3 Dr. Hrustanovic's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.4 The Company thanks Dr. Hrustanovic for his service and contributions to the Company and the Board.5

On October 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Dr. Prakash Raman to the Compensation Committee and to the Science and Technology Committee, in each case effective October 15, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OLEMA PHARMACEUTICALS, INC.

Date:

October 15, 2026

By:

/s/ Sean Bohen, M.D., Ph.D.6

Sean Bohen, M.D., Ph.D.

President and Chief Executive Officer6

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Annexon ANNX public float $244M, Jun 30, 2025
  2. DBV Technologies DBVT public float $251M, Jun 30, 2025
  3. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  4. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  5. Verastem VSTM public float $254M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.